Event-Related Potentials and Visual Spatial Attention: Influence of a Cholinergic Drug

Münte, Thomas F.; Heinze, HJ; Scholz, M. B.; Bartusch, S. M.; Dietrich, D.E.

doi:10.1159/000118559

Cited by 7 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scopolamine induces deficits characterized by reduced amplitudes and increased peak latencies (Meador et al 1989). It can be expected that cholinergic stimulation would enhance amplitudes (nonselective compounds: Dierks et al 1994;Münte et al 1988Münte et al , 1989, although for the auditory modality, a role for nicotinic receptors is less evident (Houlihan et al 1996). We cannot determine whether the lack of improvement is related to the small sample size or a ceiling effect in the groups of healthy volunteers.…”

Section: Discussionmentioning

confidence: 91%

Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers

Dunbar¹,

et al. 2007

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 91%

Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers

Dunbar¹,

et al. 2007

View full text Add to dashboard Cite

show abstract

“…The main effects of the initial values were recognized for NlOO at Fz (F=6.34, P < 0.05), Cz (F=8, P<0.05) and Pz (F=8.03, P < 0.05) for rare stimuli and at Fz ( F = 3.77, P<O.l), Cz (F=4.56, P<0.05) and Pz ( F = 9.7, P < 0.01) for frequent stimuli; for P200 at Cz (F=8.05, P<0.05) and Pz (F=16.12, P<O.Ol) for rare stimuli, and at Fz ( F = 10.91, P<O.Ol), Cz (F=8.34, P<0.05) and Pz (F=8.67, P<O.Ol) for frequent stimuli; for N200 at Fz (F=3.72, P<O.l), Cz ( F = 15.22, P<O.Ol) and Pz for rare stimuli ( F = 21.04, P<O.001); and for P300 at Fz ( F = 5.32, P<0.05), Cz ( F = l l . l l , P<O.Ol) and Pz for rare stimuli [F=10.19, P<O.Ol, df ( 1,16) in every analysis] .…”

Section: Effects Of Initial Values (Values After Placebo) On Drug Resmentioning

confidence: 99%

“…The peak amplitudes of the ERP components by LAG and HAG are shown in Table 2. Statistical analyses showed that the main effect of the group was detected for NlOO at Fz ( F = 5.17, P<O.O5) for rare stimuli and at Pz ( F = 5.75, P<O.O5) for frequent stimuli; for P200 at Cz (F=4.75, P<0.05) and Pz ( F = 10.79, P<O.Ol) for rare stimuli and at Fz (F=5.68, P<0.05) and Pz (F=6.41, P<0.05) for frequent stimuli; for N200 at Fz ( F = 10.23, P < O.Ol), Cz (F=15.22, P<O.Ol) and Pz (F= 26.03, P<O.OOl) for rare stimuli; and for P300 at Fz (F=7.1, P<0.05), Cz ( F = 11.44, P<O.Ol) and Pz (F=8.36, P<0.05) for rare stimuli [df ( 1,16) in every analysis] .…”

Section: Effects Of Initial Values (Values After Placebo) On Drug Resmentioning

confidence: 99%

Effects of the GABA Mimetic Drug, Sodium Valproate, on Event‐Related Potentials and Its Relation to the Law of Initial Value

Urasaki

Ogura

Hirano

et al. 1994

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

The effects of paminobutyric acid (GABA) mimetic drug sodium valproate (VPA) on event-related potentials (ERPs) were investigated in 18 healthy volunteers during an auditory odd ball task. VPA (200 or 400 mg) or an inactive placebo was administered according to a completely randomized double-blind, cross-over design. ERPs were recorded one hour after medication was given. VPA did not affect the latencies of N100, P200, N200 and P300.Although on the whole VPA had no effect on the amplitudes of the ERP components in the subjects, it increased the P300 amplitude in the low P300 amplitude subjects and decreased it in the high P300 amplitude subjects. This tendency toward a bidirectional response was also seen in the P200 and N200 amplitudes. It was concluded that the response which takes place being dependent on the difference in the initial values was recognized on the effect of a single administration of 200 or 400 mg VPA to ERPs. The results of this study are discussed, especially in relation to the law of initial value.

show abstract

Testing Drugs for Impaired Brain Function in Old Age: On the Effects of a Single Dose of Bifemelane using Topographic Mapping of EEG and Event-Related Potentials (P300) and Psychometric Measurements in Healthy Elderly Subjects

Semlitsch

Saletu

Anderer

et al. 1996

Hum. Psychopharmacol. Clin. Exp.

View full text Add to dashboard Cite

Clinical studies have demonstrated that bifemelane hydrochloride [4-(0-benzylphenoxy)-N-methylbutylamine hydrochloride] can improve cognitive functions in patients with various types of dementia. To elucidate specific mechanisms which may underlie the clinical benefit, the effects of bifemelane were investigated by means of computerized electroencephalography (EEG), event-related potentials (P300) and psychometry. Eighteen healthy elderly subjects, aged between 60 and 73 years, were included in a double-blind, placebo-controlled crossover study. Each subject received a single dose of 150 mg bifemelane or placebo with an interval of 1 week in between. EEG and psychometric investigations were carried out before and 2, 4, 6, and 8 h after drug administration, ERP investigations only before and 3 h after drug administration. Descriptive data analysis of the EEG showed that 150 mg bifemelane accelerated the centroid of the total frequency band, induced a significant reduction of the absolute delta + theta power and increased the absolute beta power most markedly 6 h after drug intake. Topographic analyses of ERP amplitudes showed that bifemelane did not effect ERP amplitudes. While N1, P2 and N2 latencies were not changed after bifemelane, P300 latency was shortened significantly. Psychometric investigations did not show significant or consistent effects on noopsychic and thymopsychic functions. In conclusion, bifemelane affected EEG in the sense of improved vigilance. The reduction of P300 latency may be interpreted as accelerated stimulus evaluation time, therefore indicating a beneficial effect of bifemelane on cognition at this stage of information processing. (Ogawa et al., 1992a). Moreover, bifemelane given before ischemia antagonizes learning deficits in rats (Tobe et al., 1986). Concerning bifemelane actions that may be related to cognition enhancing activity, electrophysiological studies support cholinomimetic activity (Tobe et a/., 1981;Egawa et al., 1987;Okuyama and Aihara, 1988 The authors speculated that bifemelane may act both as a metabolic activator and a vasodilator. In a study with 10 patients with Alzheimer-type dementia and 10 patients with multi-infarct dementia, eight subjects out of 20 were regarded as responders after a 3-month treatment period with a daily dosage of 150 mg bifemelane (Shigeta et al., 1993a,b). As the frequency of small rapid eye movements in the EOG increased significantly only in responders, and as only responders demonstrated a significant reduction in amplitude of the 6.0-8.0 Hz EEG frequency band, the authors concluded that part of the intellectual improvement in the patients resulted from an increased level of arousal. KEYWhile the ultimate goal in the evaluation of nootropic drugs lies in the demonstration of clinically relevant changes (Amaducci et al., 1990; Advisory Committees to the German Federal Health Office, 1992), computerized electrophysiological methods like topographic mapping of the electroencephalogram (EEG) may allow classification as well as the evaluati...

show abstract

Event-Related Potentials and Visual Spatial Attention: Influence of a Cholinergic Drug

Cited by 7 publications

References 10 publications

Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers

Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers

Effects of the GABA Mimetic Drug, Sodium Valproate, on Event‐Related Potentials and Its Relation to the Law of Initial Value

Testing Drugs for Impaired Brain Function in Old Age: On the Effects of a Single Dose of Bifemelane using Topographic Mapping of EEG and Event-Related Potentials (P300) and Psychometric Measurements in Healthy Elderly Subjects

Contact Info

Product

Resources

About